MX370788B - Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer. - Google Patents

Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.

Info

Publication number
MX370788B
MX370788B MX2016012855A MX2016012855A MX370788B MX 370788 B MX370788 B MX 370788B MX 2016012855 A MX2016012855 A MX 2016012855A MX 2016012855 A MX2016012855 A MX 2016012855A MX 370788 B MX370788 B MX 370788B
Authority
MX
Mexico
Prior art keywords
chimeric antigen
antigen receptors
cancer immunotherapy
specific chimeric
leukemia
Prior art date
Application number
MX2016012855A
Other languages
English (en)
Other versions
MX2016012855A (es
Inventor
Galetto Roman
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50486692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX370788(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis filed Critical Cellectis
Publication of MX2016012855A publication Critical patent/MX2016012855A/es
Publication of MX370788B publication Critical patent/MX370788B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

La presente invención se refiere a un receptor de antígeno quimérico (CAR) específico de CD33 caracterizado porque tiene una estructura de polipéptidos seleccionadas de V1 Y V3 como se ilustran en la figura 2, en donde dicha estructura V1 comprende (a) un dominio de unión de ligando extracelular que comprende VH y VL de un anticuerpo anti-CD33 monoclonal, (b) una bisagra Fc?RIIa, (c) un domino de transmembrana CD8a Y (d) un dominio citplásmico incluyendo un dominio de señalización CD3 zeta y un dominio coestimulatorio de 4-1BB, y en donde dicha estructura V3 comprende (s) un dominio de unión de ligando extracelular que comprende VH y VL de un anticuerpo anti-CD33 monoclonal, (b) un bisagra CD8a, (c) un dominio de transmembrana CD8a y (d) un dominio citoplásmico incluyendo un dominio de señalización CD3 zeta y un dominio coestimulatorio de 4- 1BB.
MX2016012855A 2014-04-03 2015-04-02 Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer. MX370788B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201470171 2014-04-03
PCT/EP2015/057331 WO2015150526A2 (en) 2014-04-03 2015-04-02 Cd33 specific chimeric antigen receptors for cancer immunotherapy

Publications (2)

Publication Number Publication Date
MX2016012855A MX2016012855A (es) 2016-12-12
MX370788B true MX370788B (es) 2020-01-06

Family

ID=50486692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012855A MX370788B (es) 2014-04-03 2015-04-02 Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.

Country Status (14)

Country Link
US (2) US9944702B2 (es)
EP (1) EP3126390B1 (es)
JP (1) JP6673848B2 (es)
KR (1) KR102170533B1 (es)
CN (1) CN106795221B (es)
AU (1) AU2015239069B2 (es)
BR (1) BR112016022369A2 (es)
CA (1) CA2944528C (es)
DK (1) DK3126390T3 (es)
ES (1) ES2765710T3 (es)
IL (1) IL247917B (es)
MX (1) MX370788B (es)
RU (1) RU2701341C2 (es)
WO (1) WO2015150526A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
EP3092049A1 (en) 2014-01-08 2016-11-16 Flodesign Sonics Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2945620C (en) * 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11420136B2 (en) 2016-10-19 2022-08-23 Flodesign Sonics, Inc. Affinity cell extraction by acoustics
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
CA3001859A1 (en) * 2015-10-16 2017-04-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
AU2017279548A1 (en) * 2016-06-08 2018-12-13 Precigen, Inc. Cd33 specific chimeric antigen receptors
AU2018229351B2 (en) 2017-02-28 2024-01-04 Vor Biopharma, Inc. Compositions and methods for inhibition of lineage specific proteins
CN112695050A (zh) * 2017-03-24 2021-04-23 莱蒂恩技术公司 用于用抗cd33免疫疗法治疗癌症的组合物和方法
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
EP3615076A4 (en) 2017-04-24 2021-06-02 Memorial Sloan Kettering Cancer Center ANTI-CD33 ANTIBODY AGENT
CA3063905A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
BR112020001207A2 (pt) 2017-07-20 2020-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. composições e métodos para atingir cânceres expressando cd33
US20190194340A1 (en) 2017-09-29 2019-06-27 Cell Design Labs, Inc. Methods of making bispecific anti-cd307e and anti-bcma chimeric antigen receptors and uses of the same
US20210030793A1 (en) * 2017-10-26 2021-02-04 St. Jude Children's Research Hospital, Inc. Methods and compositions for treating cd33+ cancers and improving in vivo persistence of chimeric antigen receptor t cells
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
WO2019113041A1 (en) * 2017-12-04 2019-06-13 Actinum Pharmaceuticals, Inc. Methods for treatment of patients with myelodyplastic syndromes
BR112020009889A2 (pt) 2017-12-14 2020-11-03 Flodesign Sonics, Inc. acionador e controlador de transdutor acústico
CN108047333B (zh) * 2018-01-15 2021-05-25 浙江阿思科力生物科技有限公司 以cd33为靶点的特异性抗体、car-nk细胞及其制备和应用
SG11202008796VA (en) * 2018-03-14 2020-10-29 The United States Of America As Represented By The Secretary Anti-cd33 chimeric antigen receptors and their uses
US20210015864A1 (en) 2018-03-23 2021-01-21 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
AR115052A1 (es) * 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
CN110551741A (zh) * 2018-06-01 2019-12-10 上海恒润达生生物科技有限公司 靶向cd33的嵌合抗原受体及其用途
SG11202011895VA (en) * 2018-06-04 2020-12-30 Intrexon Corp Muc16 specific chimeric antigen receptors and uses thereof
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
SG11202011751WA (en) 2018-06-22 2021-01-28 Kite Pharma Inc Chimeric transmembrane proteins and uses thereof
US11389485B2 (en) 2018-08-28 2022-07-19 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US20220098613A1 (en) * 2018-09-12 2022-03-31 Fred Hutchinson Cancer Research Center Reducing cd33 expression to selectively protect therapeutic cells
EP3870600A1 (en) 2018-10-24 2021-09-01 Obsidian Therapeutics, Inc. Er tunable protein regulation
SG11202103832SA (en) * 2018-11-07 2021-05-28 Crispr Therapeutics Ag Anti-cd33 immune cell cancer therapy
BR112021014010A2 (pt) * 2019-01-16 2021-09-21 The Trustees Of Columbia University In The City Of New York Composições e métodos para inibição de antígenos linhagem-específicos
WO2020219425A1 (en) * 2019-04-25 2020-10-29 Seattle Children's Hospital (dba Seattle Children's Research Institute) Combinatorial car t cell and hematopoeitic stem cell genetic engineering for specific immunotherapy of myeloid leukemias
WO2020243713A2 (en) * 2019-05-31 2020-12-03 City Of Hope Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
WO2021202799A2 (en) * 2020-03-31 2021-10-07 Fred Hutchinson Cancer Research Center Chimeric antigen receptors targeting cd33
US11883432B2 (en) 2020-12-18 2024-01-30 Century Therapeutics, Inc. Chimeric antigen receptor system with adaptable receptor specificity
WO2022266075A1 (en) 2021-06-14 2022-12-22 Caribou Biosciences, Inc. Methods and materials for treating cancer using car constructs with an intracellular domain comprising a stap domain and a kinase domain or a stap domain and a phosphatase domain
CN113527435B (zh) * 2021-07-14 2022-06-07 呈诺再生医学科技(珠海横琴新区)有限公司 对前列腺癌细胞特异性识别的新型多肽及其衍生物与应用
GB202204386D0 (en) * 2022-03-28 2022-05-11 Cambridge Entpr Ltd Engineered immune cell platform

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040049014A1 (en) 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
ES2166368T3 (es) * 1993-12-24 2002-04-16 Merck Patent Gmbh Inmunoconjugados.
AU2003285878B2 (en) * 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
DE102009045006A1 (de) 2009-09-25 2011-04-14 Technische Universität Dresden Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen
PL2496698T3 (pl) * 2009-11-03 2019-07-31 City Of Hope Skrócony receptor naskórkowego czynnika wzrostu (EGFRt) do selekcji transdukowanych komórek T
CN106220739A (zh) * 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
MA37681B2 (fr) 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie

Also Published As

Publication number Publication date
CN106795221B (zh) 2022-06-07
BR112016022369A2 (pt) 2017-10-10
RU2701341C2 (ru) 2019-09-25
IL247917B (en) 2020-11-30
EP3126390A2 (en) 2017-02-08
JP2017515460A (ja) 2017-06-15
US20170145094A1 (en) 2017-05-25
KR102170533B1 (ko) 2020-10-27
RU2016143155A (ru) 2018-05-04
CA2944528A1 (en) 2015-10-08
JP6673848B2 (ja) 2020-03-25
DK3126390T3 (da) 2020-01-20
WO2015150526A3 (en) 2015-11-26
CA2944528C (en) 2021-08-10
US20190002561A1 (en) 2019-01-03
US9944702B2 (en) 2018-04-17
WO2015150526A2 (en) 2015-10-08
EP3126390B1 (en) 2019-10-16
IL247917A0 (en) 2016-11-30
KR20170002412A (ko) 2017-01-06
CN106795221A (zh) 2017-05-31
ES2765710T3 (es) 2020-06-10
AU2015239069B2 (en) 2020-02-20
AU2015239069A1 (en) 2016-10-06
RU2016143155A3 (es) 2018-10-23
MX2016012855A (es) 2016-12-12

Similar Documents

Publication Publication Date Title
MX370788B (es) Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.
MX2019012244A (es) Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer.
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
MX2017001229A (es) Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer.
MX2017009181A (es) Receptores de antigenos quimericos de cadena sencilla especificos de anti-cll1 para inmunoterapia de cancer.
MX2019001184A (es) Anticuerpos anti-idiotípicos y métodos relacionados.
MX2022000132A (es) Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t.
MX2021003704A (es) Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales.
PH12017502019A1 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
CL2016002195A1 (es) Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta
MX2015015182A (es) Células efectoras inmunitarias modificadas genéticamente con el receptor de antígenos quiméricos específico de cs1.
WO2015092024A3 (en) Method of engineering multi-input signal sensitive t cell for immunotherapy
MX2018006583A (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica.
MY176294A (en) Antibodies comprising chimeric constant domains
PH12015502479B1 (en) Cd19 specific chimeric antigen receptor and uses thereof
MX2016012713A (es) Inmunoreceptores especificos de claudina-6 y epitopos de celulas t.
MX2015008740A (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
MX2020003047A (es) Nuevos anticuerpos anti-hla-a2 y usos de los mismos.
NZ750009A (en) Antibodies comprising chimeric constant domains

Legal Events

Date Code Title Description
FG Grant or registration